Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02795052 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neurologic Stem Cell Treatment Study

Study acronym: NEST
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jul 31, 2026 to Jul 31, 2027
    • Study completion date: Jul 31, 2027 to Jul 31, 2028
    • Site details revised at 1 of 3 sites
    v28
  2. Study sites: 4 to 3v27
  3. Site contacts updated at 3 of 4 sitesv26
  4. Primary completion date: Jul 31, 2025 to Jul 31, 2026
    • Study sites: 3 to 4
    • Study completion date: Jul 31, 2026 to Jul 31, 2027
    v25
  5. Primary completion date: Jul 2024 to Jul 31, 2025
    • Study completion date: Jul 2025 to Jul 31, 2026
    v24
Show 22 earlier versionsHide 22 earlier versions
  1. Primary completion date: Jul 2023 to Jul 2024
    • Study completion date: Jul 2024 to Jul 2025
    v23
  2. Re-verified, no change to tracked fieldsv22
  3. Enrollment target: 300 to 500v21 Show 8 more changesShow less
    • Primary endpoint revised
    • Primary completion date: Jun 2023 to Jul 2023
    • Study completion date: Jun 2024 to Jul 2024
    • Interventions: Intranasal BMSC (Procedure), Intravenous BMSC (Procedure) to Intravenous and Intranasal BMSC (Procedure)
    • Study description shortened, about 8 words
    • Publications: 8 to 10
    • Study arms: 2 to 1
    • Secondary endpoints shortened, about 2 words
  4. Primary completion date: Jun 2022 to Jun 2023
    • Study completion date: Jun 2023 to Jun 2024
    v20
  5. Study sites revised (3)v19
  6. Re-verified, no change to tracked fieldsv18
  7. Site details revised at 1 of 3 sitesv17
  8. Site details revised at 1 of 3 sitesv16
  9. Primary completion date: Jun 2020 to Jun 2022
    • Study sites: 2 to 3
    • Study completion date: Jun 2021 to Jun 2023
    v15
  10. 3 versions Re-verified since Oct 25, 2019, no change to tracked fieldsv12-v14
  11. Study sites revised (2)
    • Publications: 7 to 8
    • Collaborators shortened, about 3 words
    v11
  12. Re-verified, no change to tracked fieldsv10
  13. Study sites: 1 to 2v9
  14. Re-verified, no change to tracked fieldsv8
  15. Study sites: 2 to 1v7
  16. Study description shortened, about 1 wordv6
  17. Study description expanded, about 1 wordv5
  18. Lead sponsor: Retina Associates of South Florida to MD Stem Cells
    • Study sites revised (2)
    • Collaborator revised
    v4
  19. Study description expanded, about 9 wordsv3
  20. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
MD Stem Cells
4 trials monitored
See all monitored trials
Diabetes
5,087 trials monitored
See 222 trials at risk
Stroke
3,531 trials monitored
See 153 trials at risk
Dementia
1,978 trials monitored
See 106 trials at risk
and 4 more diseases
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http://mdstemcells.com/nest/
Trial Details
NCT Number NCT02795052
Lead Sponsor MD Stem Cells
Conditions
(from sponsor)		 Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders, Stroke, Traumatic Brain Injury, Cadasil, Chronic Traumatic Encephalopathy +18 more
Related terms Alzheimer Disease, Amyotrophic Lateral Sclerosis, Brain Injuries, Traumatic, Brain Ischemia, CADASIL, Cerebral Hemorrhage, Cerebral Infarction, Chronic Traumatic Encephalopathy, Cognitive Dysfunction, Dementia, Diabetic Neuropathies, Frontotemporal Dementia, Lewy Body Disease, Lewy Body Variant of Alzheimer Disease, Multiple Sclerosis, Nerve Degeneration, Nervous System Diseases, Neurodegenerative Diseases, Parkinson Disease, Shy-Drager Syndrome, Stroke, Supranuclear Palsy, Progressive
Enrollment 500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov